Abstract
Pathological remodelling of astroglia represents an important component of the pathogenesis of Alzheimer's disease (AD). In AD astrocytes undergo both atrophy and reactivity; which may be specific for different stages of the disease evolution. Astroglial reactivity represents the generic defensive mechanism, and inhibition of astrogliotic response exacerbates b-amyloid pathology associated with AD. In animal models of AD astroglial reactivity is different in different brain regions, and the deficits of reactive response observed in entorhinal and prefrontal cortices may be linked to their vulnerability to AD progression. Reactive astrogliosis is linked to astroglial Ca2+ signalling, this latter being widely regarded as a mechanism of astroglial excitability. The AD pathology evolving in animal models as well as acute or chronic exposure to β-amyloid induce pathological remodelling of Ca2+ signalling toolkit in astrocytes. This remodelling modifies astroglial Ca2+ signalling and may be linked to cellular mechanisms of AD pathogenesis.
Keywords: Alzheimer's disease, astrocyte, astroglial atrophy, astrogliosis, calcium signaling, glutamate receptors, InsP3 receptors, neuroglia, β-amyloid.
Current Alzheimer Research
Title:Calcium Signalling Toolkits in Astrocytes and Spatio-Temporal Progression of Alzheimer's Disease
Volume: 13 Issue: 4
Author(s): Dmitry Lim, J. J Rodríguez-Arellano, Vladimir Parpura, Robert Zorec, Fares Zeidán-Chuliá, Armando A. Genazzani and Alexei Verkhratsky
Affiliation:
Keywords: Alzheimer's disease, astrocyte, astroglial atrophy, astrogliosis, calcium signaling, glutamate receptors, InsP3 receptors, neuroglia, β-amyloid.
Abstract: Pathological remodelling of astroglia represents an important component of the pathogenesis of Alzheimer's disease (AD). In AD astrocytes undergo both atrophy and reactivity; which may be specific for different stages of the disease evolution. Astroglial reactivity represents the generic defensive mechanism, and inhibition of astrogliotic response exacerbates b-amyloid pathology associated with AD. In animal models of AD astroglial reactivity is different in different brain regions, and the deficits of reactive response observed in entorhinal and prefrontal cortices may be linked to their vulnerability to AD progression. Reactive astrogliosis is linked to astroglial Ca2+ signalling, this latter being widely regarded as a mechanism of astroglial excitability. The AD pathology evolving in animal models as well as acute or chronic exposure to β-amyloid induce pathological remodelling of Ca2+ signalling toolkit in astrocytes. This remodelling modifies astroglial Ca2+ signalling and may be linked to cellular mechanisms of AD pathogenesis.
Export Options
About this article
Cite this article as:
Lim Dmitry, Rodríguez-Arellano J J., Parpura Vladimir, Zorec Robert, Zeidán-Chuliá Fares, Genazzani A. Armando and Verkhratsky Alexei, Calcium Signalling Toolkits in Astrocytes and Spatio-Temporal Progression of Alzheimer's Disease, Current Alzheimer Research 2016; 13 (4) . https://dx.doi.org/10.2174/1567205013666151116130104
DOI https://dx.doi.org/10.2174/1567205013666151116130104 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Issues Impacting Therapeutic Outcomes in Pediatric Patients: An Overview
Current Pediatric Reviews Recent Advancement in Topical Drug Delivery for Psoriasis: Clinical Pertinence and Potential Market
Current Drug Targets The Role of Folate-supplementation in Depression: A Narrative Review
Current Psychopharmacology Patent Selections
Recent Patents on Nanomedicine The Flavin-Containing Monoooxygenases (FMOs): Genetic Variation and its Consequences for the Metabolism of Therapeutic Drugs
Current Pharmacogenomics Transporter-Based Delivery of Anticancer Drugs to the Brain: Improving Brain Penetration by Minimizing Drug Efflux at the Blood-Brain Barrier
Current Pharmaceutical Design Vitamin D and Infectious Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets (Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) Mammalian Nucleoside Transporters
Current Drug Metabolism Ullrich Congenital Dystrophy and Bethlem Myopathy: Current Knowledge on the Clinical Spectrum, Pathogenesis, and Future Therapeutic Avenues of Collagen VI Related Muscular Dystrophies
Current Pediatric Reviews Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy
Current Pharmaceutical Design Monobactams: A Unique Natural Scaffold of Four-Membered Ring Skeleton, Recent Development to Clinically Overcome Infections by Multidrug- Resistant Microbes
Letters in Drug Design & Discovery Clinical Significance of Thiopurine S-Methyltransferase Gene Polymorphisms
Current Pharmacogenomics The Gut Microbiota as a Target for Improved Surgical Outcome and Improved Patient Care
Current Pharmaceutical Design Short-Chain Fatty Acid Inhibitors of Histone Deacetylases: Promising Anticancer Therapeutics?
Current Cancer Drug Targets Treatment of Choroidal Neovascularization in High Myopia
Current Drug Targets Anticancer Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibitors: Current Status, Challenges and Future Prospects in Management of Epilepsy
CNS & Neurological Disorders - Drug Targets Recombinant Secretory Immunoglobulin A in Passive Immunotherapy: Linking Immunology and Biotechnology
Current Pharmaceutical Biotechnology Chimeric Antigen Receptors; Their Current and Futuristic Scope
Current Signal Transduction Therapy The Small Bowel: An Imaging Guide
Current Medical Imaging Epigenetic Effects of Cadmium in Cancer: Focus on Melanoma
Current Genomics